De Novo, Progressed, and Neglected Metastatic Castration-Sensitive Prostate Cancer: Is One Therapy Fit for All?

Clin Genitourin Cancer. 2018 Dec;16(6):482-484. doi: 10.1016/j.clgc.2018.07.014. Epub 2018 Jul 20.

Abstract

Patients who receive a diagnosis of metastatic castration-sensitive prostate cancer (CSPC) have different phenotypes of disease. Some of them have de novo CSPC, but others receive a late diagnosis, and still others underwent prostatectomy several years before the diagnosis of metastases. We analyze the presence of these differences in recent clinical trials in CSPC and assess the possible impact on their results.

Keywords: Abiraterone; CSPC; Docetaxel; HSPC; Prognosis.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / diagnostic imaging
  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / secondary
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bone Neoplasms / diagnostic imaging
  • Bone Neoplasms / drug therapy*
  • Bone Neoplasms / secondary
  • Chemotherapy, Adjuvant / methods
  • Clinical Trials as Topic
  • Disease Progression
  • Disease-Free Survival
  • Humans
  • Male
  • Patient Selection
  • Prostatectomy*
  • Prostatic Neoplasms, Castration-Resistant / pathology
  • Prostatic Neoplasms, Castration-Resistant / therapy*
  • Tomography, X-Ray Computed